Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06635902 · ClinicalTrials.gov registry record · Phase 2
Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease
A Phase 2 study of Sickle Cell Disease and Vaso-occlusive Pain Episode, sponsored by Suvankar Majumdar.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 1
- Study location
NCT06635902 is a Phase 2 study of Sickle Cell Disease and Vaso-occlusive Pain Episode that is actively recruiting participants, run by Suvankar Majumdar. The registered enrollment target is 99 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06635902, a Phase 2 study of Sickle Cell Disease and Vaso-occlusive Pain Episode, is actively recruiting participants, sponsored by Suvankar Majumdar.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if intravenous citrulline works to treat acute pain in hospitalized patients with sickle cell disease. It will also learn about the safety of intravenous citrulline. The main questions it aims to answer are: * Does intravenous citrulline decrease the duration of sickle cell pain during hospitalization * What medical problems do participants have when taking intravenous citrulline? Researchers will compare intravenous citrulline to a placebo (a look-alike substance that contains no drug) to see if intravenous citrulline works to treat acute pain. Participants will: * Receive baseline tests and intravenous citrulline for 16 hours during the hospital stay * After hospital discharge, visit the clinic in about 30 days for checkup and tests
Conditions Studied
Interventions
- OTHER Placebo
- DRUG L-citrulline
Study Locations (1)
District of Columbia
- Children's National Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2024-12-22 |
| Est. Completion | 2029-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06635902
The ClinicalTrials.gov registry entry for NCT06635902 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (66% lower). The listed sponsor is Suvankar Majumdar, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06635902 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06635902 about?
NCT06635902 is a clinical study titled "Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease". The goal of this clinical trial is to learn if intravenous citrulline works to treat acute pain in hospitalized patients with sickle cell disease. It will also learn about the safety of intravenous citrulline. The main questions it aims to answer are: * Does intravenous citrulline decrease the dura...
What is the current status of trial NCT06635902?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2024-12-22. Estimated completion is 2029-03.
What conditions does trial NCT06635902 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Vaso-occlusive Pain Episode.
What interventions are being tested in trial NCT06635902?
The interventions under investigation include: Placebo (OTHER), L-citrulline (DRUG).
Who is sponsoring clinical trial NCT06635902?
This trial is sponsored by Suvankar Majumdar, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06635902 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Explore more on PlainTrial
Sickle Cell Disease
All registered trials for this condition
Vaso-occlusive Pain Episode
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.